Athersys: Funding, Investors & Team (Aug 2026)
A clinical-stage biopharmaceutical business called Athersys has a growing pipeline of potentially best-in-class therapies that are very distinctive and intended to treat serious and life-threatening disorders. We are working to find and create novel new medications that will prolong and improve the quality of human life. We have created a pipeline of therapeutic product development programs in numerous disease areas by utilizing our patented technology. Pharmaceuticals and stem cell therapies are also part of this pathway.
Athersys has raised $17.5M across 2 funding rounds on record, the most recent an undisclosed round of $5.5M announced in Nov 2022.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Athersys Company Profile and Key Stats
Latest funding round on record: Nov 2022.
Athersys Funding Rounds
Athersys raised $12.0M in a Post-IPO Equity announced in Aug 2022.
3 months later, an undisclosed round of $5.5M was announced in Nov 2022.
Athersys Founders and Leadership Team
No contact details are on record for this team yet.
Athersys Funding Compared to Other Biotechnology Startups
Athersys' latest round of $5.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Athersys in Biotechnology and Cleveland
Companies Similar to Athersys
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Athersys Funding FAQs
What does Athersys do?
A clinical-stage biopharmaceutical business called Athersys has a growing pipeline of potentially best-in-class therapies that are very distinctive and intended to treat serious and life-threatening disorders. We are working to find and create novel new medications that will prolong and improve the quality of human life. We have created a pipeline of therapeutic product development programs in numerous disease areas by utilizing our patented technology. Pharmaceuticals and stem cell therapies are also part of this pathway.
How much funding has Athersys raised?
Athersys has raised $17.5M across 2 rounds on record. The most recent is an undisclosed round of $5.5M announced in Nov 2022.
When did Athersys last raise funding?
Athersys' most recent funding round on record is an undisclosed round of $5.5M, announced in Nov 2022.
Who is the CEO of Athersys?
William Lehmann Jr is listed as CEO at Athersys.
Where is Athersys headquartered?
Athersys is based in Cleveland, Ohio, United States.
How many employees does Athersys have?
Athersys is in the 51-100 employee band.
How does Athersys' funding compare to other Biotechnology startups?
Athersys' latest round of $5.5M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Athersys Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Athersys is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.